AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23063730 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent ADHD
Number of subjects: 765
Study 23063730 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-persistent ADHD
Number of subjects: 765
Study 23063730 — intervention group
Group type: COMPARATOR
Intervention: Non-ADHD
Number of subjects: 765
Study 23063730 — intervention group
Group type: EXPERIMENTAL
Intervention: ADHD (both persistent and non-persistent)
Number of subjects: 765
Study 23063730 — intervention group
Group type: EXPERIMENTAL
Intervention: Inattention symptoms (youth and mother-reported)
Number of subjects: 765
Study 23063730 — intervention group
Group type: EXPERIMENTAL
Intervention: Childhood hyperactivity-impulsivity symptoms
Number of subjects: 765
Study 23063730 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric comorbid conditions
Number of subjects: 765
Study 23064954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib 800 mg plus gemcitabine 1,250 mg/m(2)
Number of subjects: 22
Study 23064954 — intervention group
Group type: EXPERIMENTAL
Intervention: Pazopanib plus gemcitabine
Number of subjects: 22
Study 23065325 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration in women
Number of subjects: 186
Study 23065325 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration in men
Number of subjects: 186
Study 23065508 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor CD4(+) recent thymic emigrants
Number of subjects: 220
Study 23065508 — intervention group
Group type: EXPERIMENTAL
Intervention: Donor absolute lymphocyte count
Number of subjects: 220
Study 23065508 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymic production of regulatory T cells
Number of subjects: 220
Study 23065510 — intervention group
Group type: EXPERIMENTAL
Intervention: LEFt clinical prediction rule
Number of subjects: 157
Study 23065510 — intervention group
Group type: EXPERIMENTAL
Intervention: LEFt criteria (at least one)
Number of subjects: 157
Study 23065510 — intervention group
Group type: COMPARATOR
Intervention: No LEFt criteria (none)
Number of subjects: 157
Study 23065514 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib or Dasatinib treatment (exact dosage and duration not specified)
Number of subjects: 40
Study 23065514 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of both groups
Number of subjects: 40
Study 23065513 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferroportin Q248H
Number of subjects: 0
Study 23065513 — intervention group
Group type: COMPARATOR
Intervention: Ferroportin Q248H heterozygotes
Number of subjects: 0
Study 23065525 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin 3.2 mg/m(2) administered as a 1-hour intravenous infusion weekly on days 1, 8 and 15 every 4 weeks
Number of subjects: 67
Study 23065525 — intervention group
Group type: EXPERIMENTAL
Intervention: Plitidepsin
Number of subjects: 67
Study 23065953 — intervention group
Group type: EXPERIMENTAL
Intervention: Vinblastine and celecoxib (metronomic therapy)
Number of subjects: 35
Study 23065953 — intervention group
Group type: COMPARATOR
Intervention: Standard multiagent chemotherapy (ifosfamide-etoposide, vincristine, doxorubicin, cyclophosphamide)
Number of subjects: 35
Study 23067033 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (330-660 mg iron sulphate tablets daily for 2 months)
Number of subjects: 22
Study 23067372 — intervention group
Group type: EXPERIMENTAL
Intervention: Combinations of nanomaterial-based sensors (organically functionalized carbon nanotubes and gold nanoparticles)
Number of subjects: 57
Study 23067372 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography combined with mass spectrometry
Number of subjects: 57
Study 23067578 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-hour lactate clearance <10%
Number of subjects: 15
Study 23067578 — intervention group
Group type: COMPARATOR
Intervention: 6-hour lactate clearance ≥10%
Number of subjects: 15
Study 23067578 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between ICG-PDR and pCO2 gap
Number of subjects: 15
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute brain computed tomography or magnetic resonance imaging
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory tests (NT pro B-type natriuretic peptide, pro-atrial natriuretic peptide, creatinekinase MB, troponin T, interleukin 6, procalcitonin, high sensitive C-reactive protein, D-dimers) within 12 hours from stroke onset
Number of subjects: 500
Study 23069890 — intervention group
Group type: COMPARATOR
Intervention: Control level of cTnT after 4 hours from admission
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-acute laboratory samples (glycated haemoglobine, serum lipids) within 60 hours from stroke onset
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG) on admission and 4 hours from stroke onset
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Transesophageal or transthoracic echocardiography and 24-h ECG-Holter within 15 days from stroke onset
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurosonological examination within 60 hours from stroke onset
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography (CAG) for 30 patients with positive findings of acute myocardial ischemia
Number of subjects: 500
Study 23069890 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidemiological data acquisition
Number of subjects: 500
Study 23070347 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin microemulsion
Number of subjects: 10
Study 23071222 — intervention group
Group type: EXPERIMENTAL
Intervention: Lexatumumab (10 mg/kg, administered once every 2 weeks)
Number of subjects: 24
Study 23071272 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive chemotherapy (n = 557)
Number of subjects: 671
Study 23071272 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine or decitabine-based therapy (n = 114)
Number of subjects: 671
Study 23071272 — intervention group
Group type: EXPERIMENTAL
Intervention: Decitabine
Number of subjects: 671
Study 23071272 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 671
Study 23071495 — intervention group
Group type: EXPERIMENTAL
Intervention: Bucindolol
Number of subjects: 1040
Study 23071567 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cerebral severe malaria (NCSM)
Number of subjects: 470
Study 23071567 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral malaria (CM)
Number of subjects: 470
Study 23071567 — intervention group
Group type: COMPARATOR
Intervention: Uncomplicated malaria (UM)
Number of subjects: 470
Study 23071567 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria episode vs. healthy state
Number of subjects: 470
Study 23071567 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of UA levels with inflammatory cytokines
Number of subjects: 470
Study 23072496 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan Medoxomil (AML/OM) 5/20 mg, uptitrated to 5/40 mg, 10/40 mg, 10/40 mg + HCTZ 12.5 mg, and 10/40 mg + HCTZ 25 mg
Number of subjects: 999
Study 23072496 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/Olmesartan Medoxomil (AML/OM) ± HCTZ
Number of subjects: 999
Study 23072754 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic HEV infection
Number of subjects: 16
Study 23072754 — intervention group
Group type: COMPARATOR
Intervention: Control group (without HEV infection)
Number of subjects: 16
Study 23073921 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound elastography
Number of subjects: 128
Study 23073921 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration
Number of subjects: 128
Study 23073953 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloride-restrictive intravenous fluid strategy (lactated solution, balanced solution, chloride-poor 20% albumin)
Number of subjects: 1533
Study 23073953 — intervention group
Group type: COMPARATOR
Intervention: Chloride-liberal intravenous fluid strategy (standard intravenous fluids including chloride-rich solutions)
Number of subjects: 1533
Study 23074282 — intervention group
Group type: EXPERIMENTAL
Intervention: High-throughput sequencing method for MRD detection
Number of subjects: 106
Study 23074282 — intervention group
Group type: COMPARATOR
Intervention: Multiparameter flow cytometry
Number of subjects: 106
Study 23074282 — intervention group
Group type: COMPARATOR
Intervention: Allele-specific oligonucleotide polymerase chain reaction (ASO-PCR)
Number of subjects: 106
Study 23077008 — intervention group
Group type: EXPERIMENTAL
Intervention: MEK inhibitor treatment
Number of subjects: 3
Study 23077109 — intervention group
Group type: EXPERIMENTAL
Intervention: m-FLAI regimen (fludarabine 25 mg/m² days 1-4, cytarabine 1,000 mg/m² days 1-4, idarubicin 5 mg/m² days 1-3)
Number of subjects: 108
Study 23077109 — intervention group
Group type: EXPERIMENTAL
Intervention: m-FLAI regimen
Number of subjects: 108
Study 23077849 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV//PRP-T vaccine
Number of subjects: 123
Study 23077849 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP-IPV vaccine (second booster)
Number of subjects: 123
Study 23078588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 10 mg (for patients ≥40 kg)
Number of subjects: 606
Study 23078588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan 5 mg (for patients <40 kg)
Number of subjects: 606
Study 23078588 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (both dosages)
Number of subjects: 606
Study 23078732 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography with diameter stenosis (DS) ≥50% and FFR >0.80
Number of subjects: 1000
Study 23078732 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary angiography with diameter stenosis (DS) <50% and FFR <0.80
Number of subjects: 1000
Study 23078786 — intervention group
Group type: EXPERIMENTAL
Intervention: autologous (auto)-allogeneic (allo) tandem stem cell transplantation (SCT) with melphalan 200 mg/m(2) followed by melphalan 140 mg/m(2) and fludarabine 180 mg/m(2)
Number of subjects: 73
Study 23078786 — intervention group
Group type: EXPERIMENTAL
Intervention: achieved remission
Number of subjects: 73
Study 23078786 — intervention group
Group type: COMPARATOR
Intervention: high-risk cytogenetics (del(17p13) and/or t(4;14))
Number of subjects: 73
Study 23078909 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidofludimus 35mg once daily for 12 weeks
Number of subjects: 34
Study 23079177 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatrician advice to have a smokefree home or car or to quit smoking
Number of subjects: 1980
Study 23079177 — intervention group
Group type: EXPERIMENTAL
Intervention: Referral to a quitline or other cessation program
Number of subjects: 1980
Study 23079177 — intervention group
Group type: COMPARATOR
Intervention: Fathers
Number of subjects: 1980
Study 23079177 — intervention group
Group type: COMPARATOR
Intervention: Parents who smoked more than ten cigarettes per day
Number of subjects: 1980
Study 23080404 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz Magnetic Seizure Therapy (MST), up to 18 treatment sessions
Number of subjects: 13
Study 23080404 — intervention group
Group type: EXPERIMENTAL
Intervention: 100-Hz Magnetic Seizure Therapy (MST)
Number of subjects: 13
Study 23083061 — intervention group
Group type: EXPERIMENTAL
Intervention: TPF chemotherapy (docetaxel 30 mg/m2, cisplatin 40 mg/m2, fluorouracil 2000 mg/m2)
Number of subjects: 18
Study 23083383 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS) > 3
Number of subjects: 2674
Study 23083383 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS) > 4
Number of subjects: 2674
Study 23083383 — intervention group
Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS) > 5
Number of subjects: 2674
Study 23083383 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS cut-off points > 3 or > 4
Number of subjects: 2674
Study 23083383 — intervention group
Group type: EXPERIMENTAL
Intervention: NRS cut-off point > 5
Number of subjects: 2674
Study 23083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 5 mg in LBW patients
Number of subjects: 72
Study 23083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg in HBW patients
Number of subjects: 72
Study 23083774 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel 75 mg
Number of subjects: 72
Study 23083774 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10 mg in LBW patients
Number of subjects: 72
Study 23084712 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sodium intake quartiles
Number of subjects: 351
Study 23084712 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher potassium intake quartiles
Number of subjects: 351
Study 23084842 — intervention group
Group type: EXPERIMENTAL
Intervention: USPIO-enhanced MRI
Number of subjects: 75
Study 23085463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 5 mg for four cycles (day 100-180 after allograft)
Number of subjects: 24
Study 23085463 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide treatment
Number of subjects: 24
Study 23085463 — intervention group
Group type: COMPARATOR
Intervention: Nonresponding patients (control group)
Number of subjects: 24
Study 23087179 — intervention group
Group type: EXPERIMENTAL
Intervention: Canakinumab 150 mg subcutaneously monthly for 6 months
Number of subjects: 8
Study 23088827 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Support Grant (CSG) receipt
Number of subjects: 1148
Study 23088827 — intervention group
Group type: EXPERIMENTAL
Intervention: Possessing a birth certificate
Number of subjects: 1148
Study 23088827 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive mother
Number of subjects: 1148
Study 23088827 — intervention group
Group type: EXPERIMENTAL
Intervention: Household income below R1100
Number of subjects: 1148
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent obtained from substitute decision makers
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent obtained from patients
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Research coordinators with >10 years of experience
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Smaller intensive care units (<15 beds)
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Centers with more than 1 full-time research staff
Number of subjects: 3764
Study 23089679 — intervention group
Group type: COMPARATOR
Intervention: Centers affiliated with Canadian Critical Care Trials Group or Australian and New Zealand Intensive Care Society Clinical Trials Group
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilot trial phase
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Full trial initiation phase
Number of subjects: 3764
Study 23089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Years of recruitment
Number of subjects: 3764
Study 23091316 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary fiber intake in men
Number of subjects: 2832
Study 23091316 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein intake in women
Number of subjects: 2832
Study 23091606 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement depletion group
Number of subjects: 45
Study 23091606 — intervention group
Group type: COMPARATOR
Intervention: Non-complement depletion group
Number of subjects: 45
Study 23091606 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement C3
Number of subjects: 45
Study 23091606 — intervention group
Group type: EXPERIMENTAL
Intervention: Complement C3 depletion
Number of subjects: 45
Study 23092052 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir-based therapy (600 mg darunavir and 100 mg ritonavir twice daily)
Number of subjects: 429
Study 23092052 — intervention group
Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir-based therapy
Number of subjects: 429
Study 23092637 — intervention group
Group type: EXPERIMENTAL
Intervention: n - 3 polyunsaturated fatty acids (n - 3 PUFA) levels above the population median, C/C genotype
Number of subjects: 443
Study 23092637 — intervention group
Group type: EXPERIMENTAL
Intervention: n - 3 PUFA levels above the median, C/C genotype
Number of subjects: 443
Study 23092637 — intervention group
Group type: EXPERIMENTAL
Intervention: T-allele
Number of subjects: 443
Study 23092873 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytarabine 2 g/m(2) over 72 hours (667 mg/m(2)/24 hours) + SCH 900776 10 mg/m(2)/dose
Number of subjects: 24
Study 23093684 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced diabetic retinopathy (DR)
Number of subjects: 15773
Study 23093684 — intervention group
Group type: COMPARATOR
Intervention: Any chronic kidney disease (CKD)
Number of subjects: 15773
Study 23093684 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced diabetic retinopathy (DR) in subjects with any CKD
Number of subjects: 15773
Study 23093684 — intervention group
Group type: COMPARATOR
Intervention: Any chronic kidney disease (CKD) in individuals with advanced DR
Number of subjects: 15773
Study 23094954 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled route of application
Number of subjects: 119
Study 23094954 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual route of application
Number of subjects: 119
Study 23094954 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal route of application
Number of subjects: 119
Study 23094954 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral route of application
Number of subjects: 119
Study 23094954 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall acceptability of all routes
Number of subjects: 119
Study 23095570 — intervention group
Group type: EXPERIMENTAL
Intervention: ICECAP-O
Number of subjects: 215
Study 23095570 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 215
Study 23095978 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous intravenous infusion of recombinant human IGF-I/IGFBP-3; dosage between 21 and 111 µg/kg/24 h, median duration of 168 hours (range 47-168 hours).
Number of subjects: 5
Study 23096609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedicle nerve graft
Number of subjects: 16
Study 23096609 — intervention group
Group type: COMPARATOR
Intervention: Nonvascularized graft (sural nerve or medial antebrachial cutaneous nerve)
Number of subjects: 16
Study 23096768 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and radiation (RT)
Number of subjects: 132
Study 23096768 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU) and radiation (RT) + modified infusional 5-FU, folinic acid, and oxaliplatin chemotherapy (mFOLFOX-6)
Number of subjects: 132
Study 23096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphisms in XRCC1, XPD, and TP53
Number of subjects: 132
Study 23096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism Q399R in XRCC1
Number of subjects: 132
Study 23096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism K751Q in XPD
Number of subjects: 132
Study 23096768 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymorphism R72P in TP53
Number of subjects: 132
Study 23097223 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine in-hospital follow-up (FU) of pacemaker patients
Number of subjects: 1517
Study 23097320 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaire with 8 closed-ended (yes/no) questions focusing on cutaneous and musculoskeletal manifestations of NSF
Number of subjects: 60
Study 23097920 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 23098130 — intervention group
Group type: EXPERIMENTAL
Intervention: Pancreatic Stone Protein (PSP)
Number of subjects: 245
Study 23098130 — intervention group
Group type: COMPARATOR
Intervention: Established blood tests (e.g. White Blood Count, Neutrophils, C-reactive protein)
Number of subjects: 245
Study 23098171 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-report instruments for DDI
Number of subjects: 0
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-104 combined with gemcitabine 800 mg/m2
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-104 combined with docetaxel 60 mg/m2
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-104 combined with docetaxel 60 mg/m2 plus G-CSF
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-104 combined with docetaxel 75 mg/m2 plus G-CSF
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-104 combined with docetaxel or gemcitabine
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: FMISO scans
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: PR-104 pharmacokinetics
Number of subjects: 42
Study 23098625 — intervention group
Group type: EXPERIMENTAL
Intervention: Recommended dose for phase II trials
Number of subjects: 42
Study 23099009 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (220 mg/m² twice a day for children and 400 mg twice a day for adults) for 6 months
Number of subjects: 36
Study 23099009 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate for at least 6 months
Number of subjects: 36
Study 23099009 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events related to imatinib mesylate
Number of subjects: 36
Study 23099849 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotypic resistance-guided sequential therapy (esomeprazole and amoxicillin for 7 days, followed by esomeprazole and metronidazole plus clarithromycin, levofloxacin or tetracycline for another 7 days)
Number of subjects: 135
Study 23099849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with clarithromycin
Number of subjects: 135
Study 23099849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with levofloxacin
Number of subjects: 135
Study 23099849 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy with tetracycline
Number of subjects: 135
Study 23100308 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of α-galactosylceramide-loaded monocyte-derived dendritic cells and low-dose lenalidomide
Number of subjects: 6